Valneva SE Overview
Pro stress-test →Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. The company commercializes three approved travel vaccines (IXIARO for Japanese encephalitis, DUKORAL for cholera/traveler's diarrhea, and IXCHIQ for chikungunya) while advancing a robust pipeline of vaccine candidates including VLA15 for Lyme disease, programs for Zika, shigellosis, and other infectious diseases.
Strategic Profile
Pro stress-test →Valneva operates multi-site manufacturing infrastructure across Scotland, Sweden, and Austria, positioning it to serve global markets across North America and Europe. The company is transitioning from travel vaccine focus to address significant unmet medical needs in endemic infectious diseases, with recent positive clinical data supporting advancement of pipeline programs toward market expansion and diversification.
Competitive Landscape
Pro stress-test →Valneva competes against larger established vaccine manufacturers (Merck, GSK, Sanofi, Pfizer) in travel and infectious disease vaccines while competing with emerging biotech in niche areas like Lyme disease. The company's differentiation lies in proprietary vaccine platforms, manufacturing capabilities, and focus on unmet medical needs in neglected infectious disease areas.
Industry Context
Valneva SE operates in Specialty Vaccines / Infectious Disease Therapeutics.
Key facts
Founded: 1998 · Headquarters: Saint-Herblain, France · Employees: 676 · Revenue: $169.6M · Market cap: $0.7B